ThermoGenesis Holdings Inc. - Aset Bersih saben Siji Saham THMO

ThermoGenesis (THMO) is driving market capitalization growth through its transition to a contract bioprocessing model, as confirmed by the published book value per share, where the parameter reaches 0.12. The issuer is scaling B2B implementation of biobanking systems to expand into diagnostics, optimizing costs via component assembly outsourcing and international reagent logistics. This strategy ensures the steady accumulation of net assets without requiring significant capital expenditures.

ThermoGenesis investments in robotic cell analysis systems and the PXP platform are generating a significant volume of intangible and tangible assets. This metric measures the residual capital value per share net of liabilities, allowing for an assessment of the company's actual asset value and verification of the business's accounting reliability through book value per share.